Acadia Pharmaceuticals Inc (ACAD) 49.29 $ACAD 36.7%

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Acadia Pharmaceuticals Inc (ACAD) 49.29 $ACAD

36.7% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Fri Jul 24, 12:01PM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on April 10th, 2015 at $36.33. In approximately 4 months, Acadia Pharmaceuticals has returned 36.66% as of today's recent price of $49.64.
ACAD: 49.29 (+1.73)

Acadia Pharmaceuticals Has Returned 37.9% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Fri Jul 17, 9:54AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on April 10th, 2015 at $36.33. In approximately 3 months, Acadia Pharmaceuticals has returned 37.89% as of today's recent price of $50.09.
ACAD: 49.29 (+1.73)

Bellicum appoints Stephen R. Davis to board
M2 - Fri Jul 17, 5:34AM CDT
Biopharmaceutical company Bellicum Pharmaceuticals (Nasdaq:BLCM) disclosed on Thursday the election of Stephen R. Davis to its board of directors, including chairman of the audit committee.
ACAD: 49.29 (+1.73), BLCM: 20.17 (+1.19)

Bellicum Appoints Stephen R. Davis to Board of Directors
Business Wire - Thu Jul 16, 3:05PM CDT
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the appointment of Stephen R. Davis to its Board of Directors. Mr. Davis was also named Chairman of the Audit Committee.
ACAD: 49.29 (+1.73), BLCM: 20.17 (+1.19)

Critical Alerts For FireEye, Ariad Pharmaceuticals, ACADIA Pharmaceuticals, Esperion Therapeutics and Humana Released By InvestorsObserver
PR Newswire - Wed Jul 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, ARIA, ACAD, ESPR and HUM.
ESPR: 69.29 (-2.36), ACAD: 49.29 (+1.73), FEYE: 45.69 (-0.66), ARIA: 8.22 (+0.55), HUM: 184.17 (+0.26)

Look for Shares of Acadia Pharmaceuticals to Potentially Pullback after Yesterday's 8.71% Rise
Comtex SmarTrend(R) - Tue Jul 14, 4:56PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $44.85 to a high of $49.24. Yesterday, the shares gained 8.7%, which took the trading range above the 3-day high of $45.10 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 49.29 (+1.73)

Uptrend Call Working As Acadia Pharmaceuticals Stock Rises 14.3% (ACAD)
Comtex SmarTrend(R) - Thu Jul 02, 12:13PM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on April 10th, 2015 at $36.33. In approximately 3 months, Acadia Pharmaceuticals has returned 14.33% as of today's recent price of $41.53.
ACAD: 49.29 (+1.73)

Clinical Studies of Disease-Modifying Therapies & Drug Delivery Candidates Lead to New Drug Therapies & Patents for Treating Patients with Parkinson's Disease & Other Neurodegenerative Disorders
PR Newswire - Tue Jun 30, 9:11AM CDT
Over one million Americans suffer from the tremors, stiffness and slurred speech of Parkinson's disease and medications are usually the first-line treatment for this and other neurological conditions. Biopharmaceutical & Biotech companies continue to research through clinical studies to identify diagnostics and develop treatments designed to transform the lives of patients with severe diseases and other rare orphan conditions. Biotech companies in the news are: Amarantus BioScience Holdings, Inc. (OTC:AMBSD), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)
ACAD: 49.29 (+1.73), CPRX: 5.27 (+0.05), ACHN: 8.42 (+0.14), ADMS: 26.85 (+0.70)

ACADIA Pharmaceuticals Is Poised To Outperform The IBB Moving Forward
Brian Nichols - at Seeking Alpha - Mon Jun 22, 2:22PM CDT

ACAD: 49.29 (+1.73), IBB: 382.15 (+8.57)

Seeking Alpha's Biotech Weekly: Bubble Trouble, Allergan's Kythera Takeout, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jun 19, 3:08PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
AGN: 337.63 (+10.65), ACAD: 49.29 (+1.73), KYTH: 74.50 (+0.15), TKMR: 10.35 (+0.05), AMGN: 173.24 (+7.70), AERI: 19.08 (+0.53), TEVA: 71.12 (-0.88), LLY: 85.51 (+1.36), PRTA: 68.74 (+5.97), NVS: 102.68 (+1.14), HCC: 77.21 (+0.03)

Acadia Pharmaceuticals Up 11.7% Since SmarTrend Uptrend Call (ACAD)
Comtex SmarTrend(R) - Thu Jun 18, 9:42AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on April 10th, 2015 at $36.33. In approximately 2 months, Acadia Pharmaceuticals has returned 11.74% as of today's recent price of $40.59.
ACAD: 49.29 (+1.73)

ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 24, 2015
Business Wire - Wed Jun 17, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conference on Wednesday, June 24, 2015, at 11:00 a.m. Eastern Time in New York City.
ACAD: 49.29 (+1.73)

Acadia Pharmaceuticals Rises 1.28% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jun 16, 5:36PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $39.47 to a high of $40.81. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $39.92 on volume of 1.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 49.29 (+1.73)

Acadia Pharma's Nuplazid improves psychosis in Parkinson's patients
Seeking Alpha - at Seeking Alpha - Tue Jun 16, 11:14AM CDT

ACAD: 49.29 (+1.73)

ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID(TM) (Pimavanserin) for Parkinson's Disease Psychosis at the 19th International Congress of Parkinson's Disease and Movement Disorders
Business Wire - Tue Jun 16, 8:00AM CDT
--Data from Two Open-Label Studies Demonstrate Attractive Safety and Tolerability Profile and Potential for Long-Term Effectiveness of NUPLAZID in Parkinson's Disease Psychosis
ACAD: 49.29 (+1.73)

Psychosis - Pipeline Review, H1 2015
M2 - Wed Jun 10, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tkwp5l/psychosis) has announced the addition of the "Psychosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Psychosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psychosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Psychosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Psychosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned - Acadia Pharmaceuticals - Evotec - Heptares Therapeutics - Newron Pharmaceuticals - Reviva Pharmaceuticals - Sumitomo Dainippon Pharma For more information visit http://www.researchandmarkets.com/research/tkwp5l/psychosis
ACAD: 49.29 (+1.73)

Acadia Pharmaceuticals Falls 4.30% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 09, 5:19PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $38.60 to a high of $40.95. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $40.45 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ACAD: 49.29 (+1.73)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 238

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 0

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 0

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading